Ta strona została przetłumaczona automatycznie i dokładność tłumaczenia nie jest gwarantowana. Proszę odnieść się do angielska wersja za tekst źródłowy.

Badanie skuteczności i bezpieczeństwa PF-06741086 u dorosłych i nastolatków z ciężką hemofilią A lub umiarkowanie ciężką do ciężkiej hemofilią B

23 lipca 2026 zaktualizowane przez: Pfizer

Otwarte badanie z udziałem młodzieży i dorosłych z ciężkim stanem (aktywność czynnika krzepnięcia

Oczekuje się, że leczenie PF-06741086 przyniesie klinicznie istotną korzyść i/lub znaczący wkład w opiekę nad pacjentem w porównaniu z obecnymi metodami leczenia hemofilii A lub B, ponieważ działa inaczej niż produkty zastępujące czynnik i będzie działać w obecności inhibitorów . Możliwość podania podskórnego (SC) raz w tygodniu (QW) zapewnia opcje leczenia w przypadku braku niezawodnego dostępu naczyniowego, większą wygodę i może umożliwić lepsze przestrzeganie zaleceń. Połączenie tych cech powinno skutkować zmniejszeniem liczby epizodów krwawienia.

Przegląd badań

Status

Zakończony

Interwencja / Leczenie

Typ studiów

Interwencyjne

Zapisy (Rzeczywisty)

188

Faza

  • Faza 3

Kontakty i lokalizacje

Ta sekcja zawiera dane kontaktowe osób prowadzących badanie oraz informacje o tym, gdzie badanie jest przeprowadzane.

Lokalizacje studiów

    • Gauteng
      • Johannesburg, Gauteng, Afryka Południowa, 2193
        • Charlotte Maxeke Johannesburg Academic Hospital
      • Jeddah, Arabia Saudyjska, 21589
        • King AbdulAziz University Hospital
      • Riyadh, Arabia Saudyjska
        • King Faisal Specialist Hospital & Research Center
      • Sofia, Bułgaria, 1756
        • National Specialized Hospital for the Active Treatment of Hematological Diseases - EAD, Sofia
      • Stara Zagora, Bułgaria, 6003
        • UMHAT "Prof.Dr. Stoyan Kirkovich"
      • Beijing, Chiny, 100045
        • Beijing Children's Hospital, Capital Medical University
    • Guangdong
      • Guangzhou, Guangdong, Chiny, 510515
        • Nanfang Hospital, Southern Medical University
    • Guizhou
      • Guiyang, Guizhou, Chiny, 550004
        • The Affiliated Hospital of Guizhou Medical University
    • Jiangxi
      • Nanchang, Jiangxi, Chiny, 306113
        • Jiangxi Provincial People's Hospital
    • Tianjin Municipality
      • Tianjin, Tianjin Municipality, Chiny, 300020
        • Institute of Hematology, Chinese Academy of Medical Sciences
      • Zagreb, Chorwacja, 10000
        • Klinicki bolnicki centar Zagreb
      • Paris, Francja, 75015
        • Hôpital Necker Enfants malades
      • A Coruña, Hiszpania, 15006
        • Hospital Universitario A Coruna
      • Barcelona, Hiszpania, 08035
        • Hospital Universitario Vall d´Hebron
      • Madrid, Hiszpania, 28046
        • Hospital Universitario La Paz
      • Salamanca, Hiszpania, 37007
        • Hospital Universitario De Salamanca
      • Zaragoza, Hiszpania, 50009
        • Hospital Universitario Miguel Servet
      • Hong Kong, Hongkong
        • Queen Mary Hospital
      • Hong Kong, Hongkong
        • Prince of Wales Hospital
    • Gujarat
      • Surat, Gujarat, Indie, 395002
        • Nirmal Hospital Pvt, Ltd
    • Maharashtra
      • Pune, Maharashtra, Indie, 411004
        • Sahyadri Super Speciality Hospital
      • Pune, Maharashtra, Indie, 411004
        • Sahyadri Clinical Research And Development Center
    • Tamil Nadu
      • Vellore, Tamil Nadu, Indie, 632004
        • Christian Medical College
      • Hiroshima, Japonia, 734-8551
        • Hiroshima University Hospital
    • Aichi-ken
      • Nagoya, Aichi-ken, Japonia, 466-8560
        • Nagoya University Hospital - Transfusion Medicine
    • Hokkaido
      • Sapporo, Hokkaido, Japonia, 004-0041
        • Sapporo Tokushukai Hospital
    • Saitama
      • Iruma-gun, Saitama, Japonia, 350-0495
        • Saitama Medical University Hospital
    • Ontario
      • Hamilton, Ontario, Kanada, L8S 4K1
        • McMaster University
      • Hamilton, Ontario, Kanada, L8S 4K1
        • McMaster Children's Hospital
      • Hamilton, Ontario, Kanada, L8N 3Z5
        • McMaster University Medical Centre - Hamilton Health Sciences
      • Toronto, Ontario, Kanada, M5G 1X8
        • The Hospital for Sick Children
      • Daegu, Korea Południowa, 41944
        • Kyungpook National University Hospital
      • Seoul, Korea Południowa, 03722
        • Severance Hospital, Yonsei University Health System
      • Seoul, Korea Południowa, 05278
        • Kyung Hee University Hospital at Gangdong
    • Nuevo León
      • Monterrey, Nuevo León, Meksyk, 64460
        • Hospital Universitario "Dr Jose Eleuterio Gonzalez"
    • Yucatán
      • Mérida, Yucatán, Meksyk, 97130
        • Centro Multidisciplinario para el Desarrollo Especializado de la Inv. Clínica en Yucatán, S.C.P.
      • Muscat, Oman, 123
        • Sultan Qaboos University Hospital
      • Samara, Rosja, 443079
        • FGBOU VO "Samara State Medical University" of MoH of Russia
      • Belgrade, Serbia, 11000
        • Clinical Center of Serbia
      • Belgrade, Serbia, 11000
        • Institute for Mother and Child healthcare "Dr Vukan Cupic"
      • Kragujevac, Serbia, 34000
        • Clinical Center Kragujevac
      • Niš, Serbia, 18000
        • Clinical Center Niš
    • Florida
      • Tampa, Florida, Stany Zjednoczone, 33612
        • USF Health Morsani Center for Advanced Healthcare
    • Iowa
      • Iowa City, Iowa, Stany Zjednoczone, 52242
        • University of Iowa
    • New York
      • New Hyde Park, New York, Stany Zjednoczone, 11040
        • Northwell Health HTC
    • Washington
      • Seattle, Washington, Stany Zjednoczone, 98101
        • Washington Institute for Coagulation
      • Taichung, Tajwan, 40705
        • Taichung Veterans General Hospital
    • Changhua County
      • Changhua, Changhua County, Tajwan, 500
        • Changhua Christian Hospital
      • Adana, Turcja (Türkiye), 01130
        • Acibadem Adana Hospital
      • Ankara, Turcja (Türkiye), 06230
        • Hacettepe University Medical Faculty
      • Ankara, Turcja (Türkiye), 06500
        • Gazi University Health Research and Practice Center Gazi Hospital
      • Antalya, Turcja (Türkiye), 07060
        • Akdeniz University Medical Faculty
      • Gaziantep, Turcja (Türkiye), 27310
        • Gaziantep University Sahinbey Research and Training Hospital
      • Istanbul, Turcja (Türkiye), 34093
        • Istanbul University Oncology Institute
      • Izmir, Turcja (Türkiye), 35040
        • Ege University Medical Faculty
      • Izmir, Turcja (Türkiye), 35210
        • Dr. Behcet Uz Child Diseases Surgery Education and Research Hospital
      • Kayseri, Turcja (Türkiye), 38039
        • Erciyes University Medical Faculty
      • Samsun, Turcja (Türkiye), 55280
        • Ondokuz Mayıs University Medical Faculty
      • Trabzon, Turcja (Türkiye), 61080
        • Karadeniz Technical University Medical Faculty
      • Perugia, Włochy, 06156
        • Università degli Studi di Perugia, Azienda Ospedaliera di Perugia, Ospedale Santa Maria della
    • Milan
      • Milan, Milan, Włochy, 20122
        • Fondazione IRCCS Cà Granda Ospedale Maggiore Policlinico
    • RM
      • Roma, RM, Włochy, 00161
        • Università degli Studi di Roma "Sapienza"-Policlinico Umberto I

Kryteria uczestnictwa

Badacze szukają osób, które pasują do określonego opisu, zwanego kryteriami kwalifikacyjnymi. Niektóre przykłady tych kryteriów to ogólny stan zdrowia danej osoby lub wcześniejsze leczenie.

Kryteria kwalifikacji

Wiek uprawniający do nauki

12 lat do 74 lata (Dziecko, Dorosły, Starszy dorosły)

Akceptuje zdrowych ochotników

Nie

Opis

Kryteria przyjęcia

  • Uczestnicy z rozpoznaniem ciężkiej hemofilii A lub umiarkowanie ciężkiej do ciężkiej hemofilii B z minimalną wagą 35 kg podczas badania przesiewowego.
  • Uczestnik lub prawnie upoważniony przedstawiciel lub opiekun uczestnika, który jest w stanie wyrazić świadomą, podpisaną zgodę (lub niewielką zgodę, jeśli dotyczy).

Uczestnicy zapisani do kohorty nieinhibitorów muszą również spełniać następujące kryteria:

  • Brak wykrywalnej lub udokumentowanej historii inhibitorów
  • Uczestnicy rutynowej profilaktyki FVIII/FIX, którzy wykazali co najmniej 80% przestrzegania zaplanowanego schematu profilaktyki w ciągu 6 miesięcy przed włączeniem do badania i są chętni do kontynuowania rutynowej profilaktyki z wymianą FVIII/FIX podczas fazy obserwacyjnej.
  • Uczestnicy ze schematem leczenia na żądanie, u których wystąpiło ≥6 ostrych epizodów krwawienia (spontanicznych lub pourazowych), które wymagały wlewu czynnika krzepnięcia w okresie 6 miesięcy przed włączeniem do badania i którzy chcą kontynuować leczenie na żądanie podczas fazy obserwacyjnej.

Uczestnicy zapisani do Kohorty Inhibitorów muszą również spełniać następujące kryteria:

  • Dokumentacja aktualnego wysokiego miana inhibitora (≥5 BU/ml) lub obecnego niskiego miana inhibitora (<5 BU/ml) opornego na zastąpienie FVIII lub FIX i przywrócenie FVIII lub FIX < 60% oczekiwanego w ciągu ostatnich 6 miesięcy przed włączeniem do Faza Obserwacji
  • Pacjenci z hemofilią A leczeni zgodnie ze schematem leczenia z ≥6 epizodami krwawień lub pacjenci z hemofilią B z ≥4 epizodami krwawień (spontanicznych lub urazowych) wymagającymi leczenia czynnikiem omijającym w ciągu 6 miesięcy poprzedzających włączenie do fazy obserwacyjnej i chętni do dalszego otrzymywania -wymagane leczenie podczas fazy obserwacyjnej.
  • Uczestnicy, którzy mają udokumentowane inhibitory podczas terapii zastępczej czynnikami, ale którzy nie spełniają kryteriów ilościowych inhibitorów opisanych w poprzednim podpunkcie w czasie badania przesiewowego (np. uczestnik z wcześniej udokumentowanym wysokim mianem inhibitora (≥5 BU/ml) i których stan wyklucza ponowną prowokację z zastąpieniem FVIII lub FIX) mogą być brane pod uwagę w celu zakwalifikowania na zasadzie indywidualnych przypadków po uprzedniej zgodzie z Pfizer Medical Monitor
  • Uczestnicy, którzy spełniają wymienione powyżej kryteria krwawienia i którzy są poddawani rutynowej profilaktyce (zdefiniowanej jako leczenie poprzez dożylne wstrzyknięcie czynnika omijającego w celu zapobiegania krwawieniom) i wykazali co najmniej 80% przestrzegania zaplanowanego schematu profilaktyki w ciągu 6 miesięcy poprzedzających włączenie do badania, mogą zostać rozpatrywane pod kątem kwalifikowalności na podstawie indywidualnych przypadków po omówieniu i uzyskaniu zgody monitora medycznego firmy Pfizer.

Kryteria wyłączenia

  • Wcześniejsze lub obecne leczenie i/lub historia choroby wieńcowej, zakrzepicy żylnej lub tętniczej lub choroby niedokrwiennej
  • Znany planowany zabieg chirurgiczny w planowanym okresie badania.
  • Znana wada hemostatyczna inna niż hemofilia A lub B.
  • Nieprawidłowa czynność nerek lub wątroby
  • Obecna niestabilna choroba wątroby lub dróg żółciowych
  • Nieprawidłowe parametry hematologiczne
  • Inny ostry lub przewlekły stan medyczny lub psychiatryczny lub nieprawidłowości w wynikach badań laboratoryjnych, które mogą zwiększać ryzyko związane z udziałem w badaniu lub podawaniem produktu badanego lub mogą zakłócać interpretację wyników badania oraz, w ocenie badacza,
  • Bieżąca rutynowa profilaktyka z użyciem czynników omijających lub niekoagulacyjna terapia zastępcza bez czynników krzepnięcia lub jakiekolwiek wcześniejsze leczenie produktem terapii genowej w leczeniu hemofilii (uczestnicy leczeni profilaktycznie z użyciem czynników omijających lub którzy byli wcześniej leczeni produktami bez czynników rozpatrywane indywidualnie).
  • Regularna, jednoczesna terapia lekami immunomodulującymi

    - Trwające lub planowane stosowanie indukcji tolerancji immunologicznej podczas fazy obserwacyjnej lub fazy aktywnego leczenia lub profilaktyka polegająca na zastąpieniu FVIII lub FIX w dowolnym momencie po rozpoczęciu leczenia z interwencją badaną podczas fazy aktywnego leczenia

  • Wcześniejsza ekspozycja na PF 06741086 podczas udziału w badaniach B7841002 i B7841003.
  • Udział w innych badaniach obejmujących badane leki lub badane szczepionki w ciągu 30 dni (lub zgodnie z lokalnymi wymogami) lub 5 okresów półtrwania przed przystąpieniem do badania i/lub w trakcie udziału w badaniu.
  • Liczba komórek CD4 ≤200/ul, jeśli ludzki wirus niedoboru odporności (HIV) jest dodatni
  • Badanie przesiewowe EKG, które wykazuje istotne klinicznie nieprawidłowości, które mogą mieć wpływ na bezpieczeństwo uczestników lub interpretację wyników badania.
  • Osoby z nadwrażliwością lub reakcją alergiczną na białko chomika lub inne składniki interwencji badawczej.
  • Członkowie personelu ośrodka badawczego bezpośrednio zaangażowani w prowadzenie badania i członkowie ich rodzin, członkowie personelu ośrodka w inny sposób nadzorowani przez badacza lub uczestnicy będący pracownikami firmy Pfizer, w tym członkowie ich rodzin, bezpośrednio zaangażowani w prowadzenie badania.

Plan studiów

Ta sekcja zawiera szczegółowe informacje na temat planu badania, w tym sposób zaprojektowania badania i jego pomiary.

Jak projektuje się badanie?

Szczegóły projektu

  • Główny cel: Leczenie
  • Przydział: Nie dotyczy
  • Model interwencyjny: Zadanie krzyżowe
  • Maskowanie: Brak (otwarta etykieta)

Broń i interwencje

Grupa uczestników / Arm
Interwencja / Leczenie
Eksperymentalny: PF-06741086
Uczestnicy zostaną przydzieleni do leczenia za pomocą PF-06741086 po 6-miesięcznej fazie obserwacji ich aktualnego schematu leczenia hemofilii.
Dawka nasycająca 300 miligramów (mg) podskórnie (sc), a następnie 150 mg kw. raz w tygodniu (qw). Uczestnikom, którzy spełniają kryteria zwiększania dawki, przepisuje się 300 mg sc qw.

Co mierzy badanie?

Podstawowe miary wyniku

Miara wyniku
Opis środka
Ramy czasowe
Model-Based Annualized Bleeding Rate (ABR) of Treated Bleeding Events: Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With Prior OD Therapy at OP)
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Treated Bleeding Events: Non-Inhibitor Cohort (Participants With RP at OP)
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR is defined as number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or OD medication). A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Number of Participants With Adverse Events (AEs): Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
An AE was any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. AEs included both serious AEs and all other AEs.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Serious Adverse Events (SAEs): Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
AE: any untoward medical occurrence in a clinical study participant, temporally associated with the use of study intervention, whether or not considered related to the study intervention. SAE: any untoward medical occurrence at any dose that resulted in any of the following outcomes: death; life-threatening; required inpatient hospitalization or prolongation of existing hospitalization; persistent or significant disability/incapacity; congenital anomaly/birth defect; or that was considered as an important medical event.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Events: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic events are when a blood clot (thrombus) forms in a blood vessel in the arm, leg, lung, or head and can be life-threatening. A thrombus can occur in veins (venous thrombosis) or arteries (arterial thrombosis).
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Thrombotic Microangiopathy: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Thrombotic microangiopathy: pathological state where micro-vessels are occluded by platelet rich thrombi leading to thrombocytopenia (low platelets) and microangiopathic haemolytic anaemia (red blood cell destruction) and potential end organ damage.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Disseminated Intravascular Coagulation/ Consumption Coagulopathy: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Disseminated intravascular coagulation is characterized by widespread clotting in small blood vessels, and consumption of platelets and clotting factors by the clots, leading to bleeding.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Anti-drug Antibodies (ADA) and Neutralizing Antibodies (NAb) Against PF- 06741086: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: During prophylaxis treatment in ATP (12 months)
ADA positive: A participant with >=1 treatment induced or treatment-boosted ADA response. NAb positive: An ADA positive participant with >=1 treatment induced or treatment boosted NAb response.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Transient and Persistent ADA and NAb Against PF-06741086: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: During prophylaxis treatment in ATP (12 months)
Persistent ADA: participant with treatment-induced or treatment-boosted ADA detected at 2 or more times during treatment including any follow-up, where first and last ADA positive samples separated by >=16 weeks. Transient ADA: treatment-induced or treatment-boosted ADA detected at only 1 time during treatment or follow-up. Persistent NAb: NAb-positive participant with first and last positive NAb samples detected >=16 weeks posttreatment, irrespective of any negative samples in between. Transient NAb: NAb-positive participant with (1) treatment-induced/treatment-boosted NAb sample detected at only 1 time posttreatment or (2) treatment-induced/treatment-boosted NAb samples detected at 2 or more times where first and last positive samples separated by <16 weeks, and participant's last sample was NAb or ADA negative.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Injection Site Reactions (ISRs): Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: During prophylaxis treatment in ATP (12 months)
ISR included: injection site haematoma, injection site pain, injection site bruising, injection site erythema, injection site induration, injection site oedema, Injection site pruritus and Injection site swelling. ISR graded according to Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 where grade 1: tenderness with or without associated symptoms (warmth, erythema, itching), grade 2: pain, lipodystrophy, edema, phlebitis, grade 3: ulceration or necrosis, severe tissue damage, operative intervention indicated, grade 4: life-threatening consequences, urgent intervention indicated and grade 5: death. In this outcome measure only categories with non-zero values reported.
During prophylaxis treatment in ATP (12 months)
Number of Participants With Clinically Significant Changes in Physical Examinations: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Physical examination included assessments of the head, ears, eyes, nose, mouth, skin, heart and lung examinations, lymph nodes, gastrointestinal, musculoskeletal, and neurological systems. Height and weight were also measured and recorded. Clinical significance in physical examinations was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Changes in Vital Signs: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Vital signs included temperature, pulse rate, respiratory rate, and blood pressure. Blood pressure and pulse rate were measured in a supine position using completely automated device after at least 5 minutes of rest for the participant in a quiet setting without distractions. Respiratory rate was measured by observing and counting the respirations of the participant for 30 seconds and multiplied by 2. Clinical significance of vital signs was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Clinically Significant Abnormalities in Laboratory Parameters: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Hematology included: hemoglobin; leukocytes; neutrophils; and platelets. Chemistry included: potassium; aspartate aminotransferase; creatinine; alkaline phosphatase; total bilirubin; albumin; calcium corrected, estimated decreased; sodium; and calcium. Clinical significance of laboratory parameters was determined by investigator.
OP reporting group: Up to 6 months; ATP reporting group: up to 13 months (includes 28-35 days of safety follow-up post last dose of study drug)
Number of Participants With Severe/ Systematic Hypersensitivity and Anaphylactic Reactions: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: During prophylaxis treatment in ATP (12 months)
Systemic hypersensitivity is a complex immune response where the immune system reacts excessively to an antigen, often leading to severe allergic reactions, including widespread symptoms (which may affect multiple organs), such as rash, swelling of your face, lips, mouth, or tongue, trouble breathing, wheezing, dizziness, fainting, fast heartbeat, pounding in your chest or sweating. Anaphylaxis is a severe, potentially fatal, systemic allergic reaction that occurs suddenly after contact with an allergy causing substance.
During prophylaxis treatment in ATP (12 months)

Miary wyników drugorzędnych

Miara wyniku
Opis środka
Ramy czasowe
Model-Based ABR of Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of the following: pain or an unusual sensation in the joint, palpable swelling, and warmth of the skin over the joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Spontaneous Bleeds: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as the number of bleeds requiring treatments/ (days on treatment period/365.25). If a participant did not complete a treatment period, the days on treatment ended at the last dosing date + 6 days. Spontaneous bleed: Bleeding for no apparent/known reason particularly into the joints, muscles, and soft tissues. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Target Joint Bleeds: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete a treatment period, days on treatment ended at last dosing date + 6 days. Target joint: a major joint into which repeated bleeds occurred. Joint bleed: bleeding episode characterized by rapid loss of range of motion as compared with baseline that was associated with any combination of following: pain or unusual sensation in joint, palpable swelling, and warmth of the skin over joint. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Model-Based ABR of Total Bleeds: Inhibitor and Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
ABR: number of bleeding episodes per year. ABR was calculated as number of bleeds requiring treatments/ (days on treatment period/365.25). If participant did not complete treatment period, days on treatment ended at last dosing date + 6 days. Treated bleed: If a bleed was treated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication). Untreated bleed: If a bleed was untreated with factor replacement or bypass agents within 48 hours of start of bleeding, regardless of the type of treatment (preventive, prophylaxis or on-demand medication), it was considered as an untreated bleed. Total bleeds: Treated bleeds + untreated bleeds. A model-based ABR using a repeated measures negative binomial model is reported for this outcome measure.
OP reporting group: Up to 6 months; ATP reporting group: up to 12 months
Change From Baseline in Hemophilia Joint Health Score (HJHS) at Month 6: Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HJHS at Month 6: Inhibitor Cohort
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
HJHS evaluated total joint score for 6 joints (left ankle, right ankle, left elbow, right elbow, left knee, right knee) and the global gait score. Joint total score per joint ranged from 0 to 20 (evaluated as: swelling [0-3], duration of swelling [0-1], muscle atrophy [0-2], crepitus on motion [0-2], flexion loss [0-3], extension loss [0-3], joint pain [0-2], and strength [0-4]). Global gait score ranged from 0 to 4 based on walking, stairs, running, and hopping on 1 leg. HJHS total score was sum of total joint score for 6 joints (0 to 120) and global gait score (0 to 4). The total HJHS score ranged from 0 to 124, where higher scores indicated worse joint health.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Adults (Haem-A-QoL) Total Score and Physical Health Domain at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haem-A-QoL Total Score and Physical Health Domain at Month 6: Inhibitor Cohort, Participants >=17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haem-A-QoL assessed health-related quality of life (QoL) in adult participants (>=17 years of age) with hemophilia. It contained 46 items with 10 domains that assessed health in the following areas: physical health; feelings; view of self; sports and leisure; work and school; dealing with haemophilia; treatment; future; family planning; partnership and sexuality. All items were based on a 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then each domain score was rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A-QoL score was averaged across the 46 items values and then rescaled from 0 to 100, lower Haem-A-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Quality of Life Questionnaire for Children (Haemo-QoL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Haemo-QoL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Haemo-QoL assessed health-related QoL in adolescent participants (12 to <17 years of age) with hemophilia. It contains 12 items with 77 domains that assesses health in the following areas: physical health; feelings; attitude/view; family; friends; other people; sport and school; coping/dealing; treatment; perceived support; future and relationship. All items were based on 5-point Likert type scale (1= never, 2= rarely, 3= sometimes, 4= often, 5= all the time). Scoring was performed by averaging non-missing item responses for each domain, then rescaled from 0 to 100, lower scores signified higher QoL. Total Haem-A QoL score was averaged across the 77 items values and then rescaled from 0 to 100, lower Haemo-QoL scores signified better QoL.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Hemophilia Activities List (HAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants >=17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in HAL Total Score at Month 6: Inhibitor Cohort, Participants >=17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The HAL was a multiple domain measure of the impact of hemophilia on functional abilities in adults (>=17 years of age). The 7 domains of this instrument contained 42 items in total, as follows: lying/sitting/kneeling/standing; lower (leg) functioning; upper (arm) functioning; transportation; self-care; household tasks; and sports/leisure. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. HAL total score was sum of all items and scored 42 to 252, which were transformed to 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in Pediatric Hemophilia Activities List (pedHAL) Total Score at Month 6: Non-Inhibitor Cohort, Participants 12 to <17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in pedHAL Total Score at Month 6: Inhibitor Cohort, Participants 12 to <17 Years
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
The pedHAL was a multiple domain measure of the impact of hemophilia on functional abilities in adolescents (12 to <17 years of age). The 7 domains of this instrument contained 53 items in total, as follows: sitting/kneeling/standing; functions of the legs; functions of the arms; use of transportation; self-care; household tasks; leisure activities and sports. Items were rated on 6-point scale 1 (impossible) to 6 (never) that described difficulty due to hemophilia. pedHAL total score was normalized in a range of 0 - 100, where higher scores indicated better functional status.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Patient Global Impression of Change-Hemophilia (PGIC-H) at Month 6: Non-Inhibitor Cohort
Ramy czasowe: Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
PGIC-H at Month 6: Inhibitor Cohort
Ramy czasowe: Month 6
The PGIC-H was a single item assessment of the participant's overall impression of change in their life with hemophilia, on a 7-point scale (1= greatly improved to 7= greatly worsened, where lower scores indicated better improvement).
Month 6
Change From Baseline in EuroQol 5 Dimensions 5 Level (EQ-5D-5L) Index and VAS Scores at Month 6: Non-Inhibitor Cohort
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
Change From Baseline in EQ-5D-5L Index and VAS Scores at Month 6: Inhibitor Cohort
Ramy czasowe: OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6
EQ-5D-5L consisted of participant completed questionnaire with 2 components: health state profile index and visual analogue scale (VAS). EQ-5D health state profile index has 5 domains (mobility, self-care, usual activities, pain/discomfort, anxiety/depression), with 5 levels (1= no problems, 2= slight problems, 3= moderate problems, 4= severe problems, 5= extreme problems). Responses to 5 dimensions comprised health state index value. E.g. if a participant responds "no problems" for each 5 dimensions, then health state was coded as "11111" with predefined index value to it. EQ-5D-5L index score ranged from -0.594 to 1, United Kingdom look-up value was applied to all participants, higher scores indicated better health states. The EQ- VAS measured participant's self-rated health state on a scale from 0 (worst imaginable health state) to 100 (best imaginable health state) by VAS, where higher scores indicated better heath states.
OP reporting group: Baseline (Day 1, day of study enrollment), Month 6; ATP reporting group: Baseline (before dose on Day 1 of ATP), Month 6

Współpracownicy i badacze

Tutaj znajdziesz osoby i organizacje zaangażowane w to badanie.

Sponsor

Śledczy

  • Dyrektor Studium: Pfizer CT.gov Call Center, Pfizer

Publikacje i pomocne linki

Osoba odpowiedzialna za wprowadzenie informacji o badaniu dobrowolnie udostępnia te publikacje. Mogą one dotyczyć wszystkiego, co jest związane z badaniem.

Daty zapisu na studia

Daty te śledzą postęp w przesyłaniu rekordów badań i podsumowań wyników do ClinicalTrials.gov. Zapisy badań i zgłoszone wyniki są przeglądane przez National Library of Medicine (NLM), aby upewnić się, że spełniają określone standardy kontroli jakości, zanim zostaną opublikowane na publicznej stronie internetowej.

Główne daty studiów

Rozpoczęcie studiów (Rzeczywisty)

9 marca 2020

Zakończenie podstawowe (Rzeczywisty)

29 kwietnia 2025

Ukończenie studiów (Rzeczywisty)

29 kwietnia 2025

Daty rejestracji na studia

Pierwszy przesłany

2 maja 2019

Pierwszy przesłany, który spełnia kryteria kontroli jakości

2 maja 2019

Pierwszy wysłany (Rzeczywisty)

6 maja 2019

Aktualizacje rekordów badań

Ostatnia wysłana aktualizacja (Rzeczywisty)

14 sierpnia 2026

Ostatnia przesłana aktualizacja, która spełniała kryteria kontroli jakości

23 lipca 2026

Ostatnia weryfikacja

1 lipca 2026

Więcej informacji

Terminy związane z tym badaniem

Plan dla danych uczestnika indywidualnego (IPD)

Planujesz udostępniać dane poszczególnych uczestników (IPD)?

TAK

Opis planu IPD

Firma Pfizer zapewni dostęp do danych poszczególnych uczestników, których dane identyfikacyjne zostały pozbawione elementów umożliwiających identyfikację, oraz związanych z nimi dokumentów badawczych (np. protokół, plan analizy statystycznej (SAP), raport z badania klinicznego (CSR)) na żądanie wykwalifikowanych badaczy i z zastrzeżeniem pewnych kryteriów, warunków i wyjątków. Więcej informacji na temat kryteriów udostępniania danych przez firmę Pfizer oraz procesu ubiegania się o dostęp można znaleźć na stronie: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.

Informacje o lekach i urządzeniach, dokumenty badawcze

Bada produkt leczniczy regulowany przez amerykańską FDA

Tak

Bada produkt urządzenia regulowany przez amerykańską FDA

Nie

Te informacje zostały pobrane bezpośrednio ze strony internetowej clinicaltrials.gov bez żadnych zmian. Jeśli chcesz zmienić, usunąć lub zaktualizować dane swojego badania, skontaktuj się z register@clinicaltrials.gov. Gdy tylko zmiana zostanie wprowadzona na stronie clinicaltrials.gov, zostanie ona automatycznie zaktualizowana również na naszej stronie internetowej .

Subskrybuj